Disc Medicine nabs cash, big backers and biopharma drug deal

By Ben Adams | FierceBiotech | October 29, 2019

Not a bad day’s work for Atlas-seeded startup Disc Medicine: It’s managed a healthy $50 million series A, led by Novo Nordisk’s VC arm, gained a new executive chair from Nimbus and nabbed a deal with AbbVie.

The Cambridge, Massachusetts-based biotech’s pipeline is focused on the hepcidin pathway, aimed at finding and working out new therapies against ineffective red blood cell production.

Read full article here.

By MIT Sloan CDO